Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the week of December 22–26, 2025 with a familiar setup for biotech investors: a cash-rich market leader in cystic fibrosis (CF), a pipeline that could meaningfully diversify revenue over the next 12–24 months, and a stock that can move quickly on headlines—even when broader markets are quiet. The difference this time is the calendar. U.S. equities trading will be compressed by Christmas, with an early close on Wednesday, Dec. 24 (1:00 p.m. ET) and markets closed Thursday, Dec. 25. That tends to thin liquidity and can magnify price swings—up or down—on even modest